ALKS Stock: Price, Earnings History and SEC Filings
Alkermes plc (ALKS) last traded at $45.34, down 0.07% on the latest session and up 11.9% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.00 against an analyst estimate of $-0.04, a beat of 100.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ALKS earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 28, 2026 | $0.00 | $-0.04 | +100.00% |
| Mar 2026 | May 5, 2026 | $-0.40 | $-0.57 | +29.82% |
| Dec 2025 | Feb 25, 2026 | $0.34 | $0.31 | +9.68% |
| Sep 2025 | Oct 28, 2025 | $0.49 | $0.34 | +44.12% |
ALKS beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How ALKS reacts to earnings
Across its last 8 earnings releases, ALKS moved 4.1% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-07-28 | Before open | -4.23% |
| 2026-05-05 | Before open | +6.09% |
| 2026-02-25 | Before open | -7.04% |
| 2026-01-12 | Before open | -0.13% |
| 2025-10-28 | Before open | +4.31% |
| 2025-10-22 | Before open | -1.14% |
| 2025-07-29 | Before open | +3.25% |
| 2025-05-01 | Before open | +6.29% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
ALKS financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $1.5B | $242M | $480M | 16.4% | $1.43 |
| 2024 | $1.6B | $367M | $406M | 23.6% | $2.17 |
| 2023 | $1.7B | $356M | $353M | 21.4% | $2.10 |
| 2022 | $1.1B | -$158M | -$17M | -14.2% | $-0.97 |
| 2021 | $1.2B | -$48M | $74M | -4.1% | $-0.29 |
| 2020 | $1.0B | -$111M | $41M | -10.7% | $-0.70 |
| 2019 | $1.2B | -$197M | -$19M | -16.8% | – |
| 2018 | $1.1B | -$139M | $30M | -12.7% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for ALKS
- 8-K · Sep 21, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Sep 16, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Aug 12, 2026Material agreement, Financial statements and exhibits
- 10-Q · Jul 28, 2026
- 8-K · Jul 28, 2026Results of operations, Financial statements and exhibits
- 8-K · Jul 8, 2026Agreement terminated
- 8-K · Jun 15, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · May 20, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
- 8-K · May 12, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 10-Q · May 5, 2026
Insider filing activity
ALKS insiders filed 7 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
ALKS news
- Alkermes (ALKS) Starts Phase 2 MDD Trial, Is The Upside Already Priced In?Oct 31, 2026 · finance.yahoo.com
- Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)Oct 30, 2026 · finance.yahoo.com
- Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top EstimatesOct 29, 2026 · finance.yahoo.com
- Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to DeclineOct 27, 2026 · finance.yahoo.com
- Alkermes to Report Third Quarter Financial Results on November 3, 2026Oct 20, 2026 · finance.yahoo.com
- Earnings Preview: Alkermes (ALKS) Q3 Earnings Expected to DeclineOct 20, 2026 · finance.yahoo.com
About Alkermes plc
Alkermes plc (ALKS) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. Its fiscal year ends in December.